4Kulke M, Bergsland E, Ryan DP, et al. A phase Ⅱ, open-label,safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc Am Soc Clin Oncol, 2003, 22: 239.
5Fossella FV. Docetaxel in second-line treatment of non-small-cell lung cancer. Clin Lung Cancer, 2002, 3 (Suppl 2) :S23-28.
6Gebbia V,Galetta D, Riccardi F, et al. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage Ⅲ B- Ⅳ non-small cell lung carcinoma: a prospective randomized study[J]. Lung Cancer ,2002,37(2): 179 - 187.
7Fossella F, Pereira JR, yon Pawel J, et al. Randomized, multinational, phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group [ J ]. J Clin Oncol, 2003,21 (16) :3016 - 3024.
8Chen YM,Lee CS, Lin WC. Phase Ⅱ study with vinorelbine and cisplatin in advanced non-small cell lung cancer after failure of previous chemotherapy [ J ]. J Chin Med Assoc, 66 ( 4 ): 241 - 246.
9Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[ J ]. N Engl J Med , 2004,350 (23): 2335 - 2342.
10Sim BK, MacDonald NJ, Gubish ER. Angiostatin and endostatin: Endogenous inhibitors of tumour growth[J]. Cancer Metastasis Rev, 2000,19 ( 1 - 2): 181 - 190.
